Physician profile
Daniel A Brill
NPI 1457700445
$3,416.47
in general payments reported to CMS, 2019-2025
17 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $317 · 2021: $141 · 2022: $1,094 · 2023: $389 · 2024: $140 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $680.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $872.30 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $650.70 | 2019-2025 | Eylea, Eylea Hd |
| Eyepoint US, INC. | $406.07 | 2021-2023 | |
| Genentech USA, INC. | $293.66 | 2022-2025 | Vabysmo, Susvimo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $255.40 | 2019-2020 | |
| Alimera Sciences, INC. | $232.08 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $183.27 | 2022 | |
| Apellis Pharmaceuticals, INC. | $106.20 | 2022 | |
| Abbvie INC. | $95.55 | 2023-2025 | Ozurdex |
| Coherus Oncology, INC. | $76.15 | 2022 | |
| Astellas Pharma US INC | $64.00 | 2024-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $62.52 | 2019 | |
| Biotissue Holdings INC. | $30.94 | 2023 | |
| Ivantis, INC | $28.04 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $23.06 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $22.08 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.